Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OMS721 (narsoplimab) in atypical hemolytic uremic syndrome
NCT03205995Phase 3Terminated
- Sponsor
- Omeros Corporation
- Start
- May 2018
- Primary completion
- Feb 2021
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 4
01
Overview
A Phase 3 trial of narsoplimab in atypical hemolytic uremic syndrome (aHUS), sponsored by Omeros Corporation. Started May 2018; status: terminated.
02
Drugs
narsoplimab
03
Conditions
atypical hemolytic uremic syndrome (aHUS)
Beyond the preview
Go deeper on NCT03205995.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03205995.